MLH3 and cancer: Additionally, mismatch repair members outside of current GWAS hits, such as MLH3, could also be assessed in the future.42 Adverse safety profiles should still be evaluated, especially for DNA repair genes, mainly since oncology-related targets are also associated with risks.10 Finally, the identified RRM2B-related ribonucleotide reductase inhibitors in clinical development as cancer treatments may also have safety concerns as neurological disease treatments.